



Heart and Obstructive Sleep Apnea: a Common Relationship

Glaucylara Reis Geovanini*

Department of Genetics and Molecular Cardiology, University of São Paulo, Brazil

Editorial

Obstructive Sleep Apnea (OSA) is a clinical condition characterized by partial (hypopneas) or complete (apneas) intermittent occlusions of the upper airway during sleep. These lead to intermittent hypoxia, sleep fragmentation, and promote abrupt reductions of intrathoracic pressure [1]. OSA is common not only in the general population (9% women and 17% men), but particularly in patients with Cardiovascular Disease (CVD) [2-5]. For instance, around 50% of patients with hypertension and 30% of patients with heart failure have some degree of OSA [3-5]. OSA is also highly prevalent among patients with chronic and stable Coronary Artery Disease (CAD) [6-8]. Growing evidence suggests that OSA is associated with increased risk of major cardiovascular events, including myocardial infarction and stroke [9,10]. In addition, observational studies have shown that the main treatment of OSA, Continuous Positive Airway Pressure (CPAP), can reduce non-fatal and fatal cardiovascular events in patients with severe forms of OSA [11]. However, randomized clinical trials did not show the favorable effect of CPAP on the CVD scenario [12-15]. The most likely explanation was the lower adherence rate, since in the subgroup analysis those who used CPAP more than 4 hours/night had cardiovascular improvement [12-15]. Therefore, there is still a need for clarification on the underlying mechanisms that link OSA and CVDs. The pivotal mechanisms linking OSA and CVDs are intermittent hypoxia, oxidative stress, inflammation, sympathetic activation and endothelial dysfunction [12]. OSA has been associated with elevated inflammation markers and the treatment of OSA with CPAP has shown reduced levels of inflammatory biomarkers [16-18]. As inflammation plays a major role in the atherosclerosis it seems reasonable that inflammation may be a pathway linking OSA and CVDs [19,20]. Recently, it has been reported that OSA is independently associated with higher serum levels of neutrophil and the sympathetic nervous system partially mediates this association [17]. Further research is therefore needed to establish the main pathways linking OSA and CVDs, which may lead to future targeted therapies. Immune markers may improve the risk stratification of OSA-CVD susceptibility. OSA is characterized by repetitive events of apneas and hypopneas during sleep, which generates intermittent hypoxia, exaggerated negative intrathoracic pressure, and arousals from sleep. As a result, this cascade of events may increase myocardial demand [1,2,12]. My colleagues and I showed that very severe OSA was independently associated with overnight myocardial injury in patients with refractory angina [7]. In addition, population-based studies have found that OSA correlated with low limit detection levels of cardiac troponin, characterizing a subclinical myocardial damage [21-23]. In the era of precision medicine, better understanding of the individual susceptibility of OSA among CVD settings may clarify mechanistic pathways targeting therapies.

OPEN ACCESS

*Correspondence:

Glaucylara Reis Geovanini, Department of Genetics and Molecular Cardiology, University of São Paulo, Av Dr Eneas de Carvalho Aguiar, 44, 10th Floor, Bl 2, 05403-000, Brazil, Tel: +55 11 2661-5511;

E-mail: gal.geovanini@gmail.com

Received Date: 28 Mar 2018

Accepted Date: 24 Apr 2018

Published Date: 26 Apr 2018

Citation:

Geovanini GR. Heart and Obstructive Sleep Apnea: a Common Relationship. *Ann Clin Anesth Res.* 2018; 2(1): 1010.

Copyright © 2018 Glaucylara Reis Geovanini. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

References

1. Dempsey JA, Veasey SC, Morgan BJ, O'Donnell CP. Pathophysiology of sleep apnea. *Physiol Rev.* 2010;90(1):47-112.
2. Peppard PE, Young T, Barnet JH, Palta M, Hagen EW, Hla KM. Increased prevalence of sleep-disordered breathing in adults. *Am J Epidemiol.* 2013;177(9):1006-14.
3. Drager LF, Genta PR, Pedrosa RP, Nerbas FB, Gonzaga CC, Krieger EM, et al. Characteristics and predictors of obstructive sleep apnea in patients with systemic hypertension. *Am J Cardiol.* 2010;105(8):1135-9.
4. Yumino D, Wang H, Floras JS, Newton GE, Mak S, Ruttanaumpawan P, et al. Prevalence and physiological predictors of sleep apnea in patients with heart failure and systolic dysfunction. *J Card Fail.* 2009;15(4):279-85.
5. MacDonald M, Fang J, Pittman SD, White DP, Malhotra A. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. *J Clin Sleep Med.* 2008;4(1):38-42.
6. Valham F, Moore T, Rabben T, Stenlund H, Wiklund U, Franklin KA. Increased risk of stroke in patients with

- coronary artery disease and sleep apnea: a 10-year follow-up. *Circulation*. 2008;118(9):955-60.
7. Geovanini GR, Pereira AC, Gowdak LH, Dourado LO, Poppi NT, Venturini G, et al. Obstructive sleep apnoea is associated with myocardial injury in patients with refractory angina. *Heart*. 2016;102(15):1193-9.
 8. Geovanini GR, Gowdak LHW, Pereira AC, Danzi-Soares NJ, Dourado LOC, Poppi NT, et al. OSA and depression are common and independently associated with refractory angina in patients with coronary artery disease. *Chest*. 2014;146(1):73-80.
 9. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. *Lancet*. 2005;365(9464):1046-53.
 10. Yaggi HK, Concato J, Kernan WN, Lichtman JH, Brass LM, Mohsenin V. Obstructive sleep apnea as a risk factor for stroke and death. *N Engl J Med*. 2005;353(19):2034-41.
 11. Wang J, Yu W, Gao M, Zhang F, Li Q, Gu C, et al. Continuous positive airway pressure treatment reduces cardiovascular death and non-fatal cardiovascular events in patients with obstructive sleep apnea: A meta-analysis of 11 studies. *Int J Cardiol*. 2015;191:128-31.
 12. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S, et al. Sleep Apnea: Types, Mechanisms, and Clinical Cardiovascular Consequences. *J Am Coll Cardiol*. 2017;69(7):841-58.
 13. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X, et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. *N Engl J Med*. 2016;375(10):919-31.
 14. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-Alonso M, Carmona C, Barceló A, et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. *JAMA*. 2012;307(20):2161-8.
 15. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea: the RICCADSA randomized controlled trial. *Am J Respir Crit Care Med*. 2016;194(5):613-20.
 16. Nadeem R, Molnar J, Madbouly EM, Nida M, Aggarwal S, Sajid H, et al. Serum inflammatory markers in obstructive sleep apnea: a meta-analysis. *J Clin Sleep Med*. 2013;9(10):1003-12.
 17. Geovanini GR, Wang R, Weng J, Tracy R, Jenny NS, Goldberger AL, et al. Elevations in neutrophils with obstructive sleep apnea: The Multi-Ethnic Study of Atherosclerosis (MESA). *Int J Cardiol*. 2018;257:318-323.
 18. Xie X, Pan L, Ren D, Du C, Guo Y. Effects of continuous positive airway pressure therapy on systemic inflammation in obstructive sleep apnea: a meta-analysis. *Sleep Med*. 2013;14(11):1139-50.
 19. Libby P, Nahrendorf M, Swirski FK. Leukocytes Link Local and Systemic Inflammation in Ischemic Cardiovascular Disease: An Expanded "Cardiovascular Continuum". *J Am Coll Cardiol*. 2016;67(9):1091-103.
 20. Libby P. Inflammation in atherosclerosis. *Arterioscler Thromb Vasc Biol*. 2012;32(9):2045-51.
 21. Querejeta Roca G, Redline S, Punjabi N, Claggett B, Ballantyne CM, Solomon SD, et al. Sleep apnea is associated with subclinical myocardial injury in the community. The ARIC-SHS study. *Am J Respir Crit Care Med*. 2013;188(12):1460-5.
 22. Einvik G, Røsjø H, Randby A, Namtvedt SK, Hrubos-Strøm H, Brynildsen J, et al. Severity of obstructive sleep apnea is associated with cardiac troponin I concentrations in a community-based sample: data from the Akershus Sleep Apnea Project. *Sleep*. 2014;37(6):1111-6.
 23. Randby A, Namtvedt SK, Einvik G, Hrubos-Strøm H, Hagve TA, Somers VK, et al. Obstructive sleep apnea is associated with increased high-sensitivity cardiac troponin T levels. *Chest*. 2012;142(3):639-46.